FY2025 · ended Dec 31, 2025 · Revenue $3.55M, -46.2% YoY · Filed Mar 18, 2026
Marker Therapeutics, Inc. (MRKR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.5 million and a net loss of $12.2 million.
Revenue (TTM)
$3.95M
-30.7% vs year-ago TTM
Net income (TTM)
$-10.90M
+14.8% vs year-ago TTM
Operating cash flow (TTM)
$-9.76M
+10.4% vs year-ago TTM
Free cash flow
$-18.66M
-27.6% vs prior year
EPS (TTM)
$-0.63
+53.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
16.67M
+55.7% vs prior year
Net cash
$4.17M
FY 2022
Operating margin
-304.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRKR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1094038
- Former names
- TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M |
| Diluted EPS | -$0.79 | -$1.19 | -$0.94 | -$3.58 | -$5.47 |
| Operating cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M |
| Stockholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M |
| Cash and investments | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M |
| Total debt | — | — | — | $7.6M | $11.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 4, 2026 | May 1, 2026 |
| ARS | Annual report to shareholders | Mar 20, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 18, 2026 |
All 904 Marker Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.